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Background: Since 2008, Arthritis Research UK have utilised the valuable experience and perspective of people with arthritis to review and evaluate the research applications we receive, through the USER stakeholder committee. The world of public and patient involvement (PPI) has developed and progressed hugely in that time. So too has Arthritis Research UK, becoming an insight-led charity that can now genuinely say that people with arthritis are at the centre of everything we do, helping those people to be in control, independent and recognised. As such, our approach to PPI must not only meet the new high standards of meaningful PPI set by the research community but also serve to anchor our research activities and the work that we fund in genuine relevance and patient benefit. Objectives: To present our new approach to involving people with arthritis in the decision-making processes of research and the wider charity.
Methods:
We carried out a UK-wide scoping exercise, consisting of questionnaires and one-to-one interviews, of key stakeholder groups and PPI leaders. This included: our funded researchers and centres of excellence; medical research charities; and people with arthritis including ex-and current USER members. The findings were written up in to a report. Results: The findings of the report highlighted to us that we need to 1) scale up our PPI activities in order to ensure that insight of people with arthritis can be integrated at all stages of the research cycle 2) improve the quality of our PPI ensuring that all the things we do are carried out with clear purpose, that they are meaningful and add mutual value to all involved 3) increase the numbers of people with arthritis in our PPI group to help realise this vision, whilst improving our support, training and guidance processes for those people 4) recognise and support the already excellent PPI activities going on in the musculoskeletal community, and providing resources and training for those also wishing to start or improve PPI activities. Conclusions: After implementing this new approach for over a 18 months, we are now confident that our research activities and the research we fund, have the utmost relevance and potential benefit to people with arthritis. Background: Exercise therapy is recommended for people with axSpA [1]. In the Netherlands GET specifically for patients with axSpA is usually organized by local rheumatology patient organizations. New scientific insights into the delivery of GET have emerged over the past years and structural reimbursement from the basic health insurance was terminated. To ensure the quality and continuity of the delivery of GET it is necessary first to determine their current structure and processes. Objectives: To describe the structure and processes of group exercise therapy specifically for patients with axSpA in the Netherlands. Methods: Using the database of the Dutch Arthritis Foundation in 2016 a pen-and-paper questionnaire was sent to the coordinators of all 82 local patient organizations who could potentially be involved in the delivery of AxSpA GET. The questionnaire comprised 18 questions on the numbers of groups and participating patients, organizational and financial responsibilities, recruitment methods for participants and supervisors, the type of exercise therapy provided (land based, hydrotherapy or a combination of both) and the perceived threats for future continuation. Results: The questionnaire was returned by 66 of the 82 coordinators of whom17 stated their organization was involved in the delivery of axSpA specific GET (45 group therapy classes: 1 only land exercises; 13 only hydrotherapy; 31 combination) for 496 patients (estimated number of patients with axSpA in the Netherlands in 2016: 61.200 [2] ). 15/17 local patient organisations have organisational as well as financial responsibilities. The most often used recruitment methods for participants were: via the rheumatologist/rheumatology nurses (n=17), physical therapists (n=8), or advertisement in local patient organisations' own media (n=8). Recruitment of supervisors was most often done by asking around within their own network (n=14) or asking the leaving supervisor for replacement (n=8). Regular evaluation of the delivery of care with the supervisors and participants was performed by 10 and 12 local patient organizations, respectively. Three had an agreement with health insurance companies regarding reimbursement of GET. In 6 regions the number of participants had been declining over the past 5 years. The most mentioned threats for continuity by coordinators were financial difficulties (n=7) and recruiting participants (n=9). Conclusions: 17 local rheumatology patient organizations involved in the delivery of GET specifically for patients with axSpA in the Netherlands were identified. The large majority played an active role in the organization and reimbursement and regular evaluation of care delivery was done by two-thirds of them. Future challenges are the recruitment of new participants and reimbursement. As only a small minority of AxSpA patients appears to take part in group exercise therapy, more insight into the needs and preferences among the larger population is needed. 
